ASCOT: CRP Does Not Improve Upon Standard Framingham Score
November 23, 2010 | Hospitalist News (Archived)
Author and Disclosure Information
FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION
He agreed with Dr. Sever and Dr. Lloyd-Jones that the message from ASCOT regarding the use of on-treatment CRP to titrate statin therapy is that it doesn’t make sense.
Dr. Sever declared that he is a consultant to and is on the speakers bureau for Pfizer, which sponsored the ASCOT trial. Dr. Cannon is also on the speakers bureau for Pfizer. Dr. Lloyd-Jones reported no relevant financial interests.
